MOUNTAIN VIEW, Calif. - Alto Neuroscience, Inc. (NYSE: ANRO), currently trading at $3.11 and down nearly 26% over the past week, has announced the continuation of its Phase 2b clinical trial for ...

“We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion’s CEO. “Don’s track record of strategic and operational financial leadership, coupled with his extensive experience as ...